Tinavi Medical Technologies Co.,Ltd. (SHA:688277)
China · Delayed Price · Currency is CNY 20.42
+0.41 (2.05%)
May 8, 2026, 3:00 PM CST
SHA:688277 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 278.82 | 172.59 | 206.71 | 145.48 | 145.6 |
Other Revenue | - | 6.25 | 3.33 | 10.71 | 10.43 |
| 278.82 | 178.84 | 210.04 | 156.19 | 156.02 | |
Revenue Growth (YoY) | 55.90% | -14.85% | 34.48% | 0.11% | 14.80% |
Cost of Revenue | 85.81 | 54.18 | 71.11 | 54.02 | 50.04 |
Gross Profit | 193 | 124.66 | 138.92 | 102.17 | 105.98 |
Selling, General & Admin | 246.09 | 188.11 | 217.47 | 164.98 | 140.57 |
Research & Development | 123.17 | 85.6 | 134.5 | 114.59 | 101.61 |
Other Operating Expenses | -32.49 | 2.48 | -3.84 | -0.3 | -1.27 |
Operating Expenses | 336.77 | 282.39 | 350.52 | 277.04 | 246.84 |
Operating Income | -143.77 | -157.73 | -211.6 | -174.87 | -140.86 |
Interest Expense | - | -9.14 | -6.43 | -3.95 | -3.35 |
Interest & Investment Income | - | 41.39 | 58.97 | 1.36 | 8.73 |
Earnings From Equity Investments | 2.73 | - | - | - | - |
Currency Exchange Gain (Loss) | - | 1.16 | 0.72 | 3.15 | -0.9 |
Other Non Operating Income (Expenses) | -13.94 | -0.09 | -0.06 | -0.04 | -0.05 |
EBT Excluding Unusual Items | -154.97 | -124.42 | -158.39 | -174.36 | -136.43 |
Gain (Loss) on Sale of Investments | 0.67 | 0.05 | 0.09 | 0.1 | 0.63 |
Gain (Loss) on Sale of Assets | 0 | 5.39 | -0.03 | -0.05 | -0.17 |
Asset Writedown | -0.38 | - | - | - | - |
Other Unusual Items | - | 19.44 | 7.65 | 30.15 | 31.32 |
Pretax Income | -154.69 | -99.55 | -150.69 | -144.16 | -104.65 |
Income Tax Expense | 41.42 | 21.58 | 10.61 | -31.82 | -22 |
Earnings From Continuing Operations | -196.11 | -121.13 | -161.3 | -112.34 | -82.65 |
Minority Interest in Earnings | 13.36 | - | 4.91 | 1.75 | 2.72 |
Net Income | -182.75 | -121.13 | -156.39 | -110.58 | -79.93 |
Net Income to Common | -182.75 | -121.13 | -156.39 | -110.58 | -79.93 |
Shares Outstanding (Basic) | 457 | 449 | 447 | 425 | 421 |
Shares Outstanding (Diluted) | 457 | 449 | 447 | 425 | 421 |
Shares Change (YoY) | 1.84% | 0.40% | 5.05% | 1.10% | 8.13% |
EPS (Basic) | -0.40 | -0.27 | -0.35 | -0.26 | -0.19 |
EPS (Diluted) | -0.40 | -0.27 | -0.35 | -0.26 | -0.19 |
Free Cash Flow | -80.88 | -135.34 | -391.53 | -147.1 | -316.42 |
Free Cash Flow Per Share | -0.18 | -0.30 | -0.88 | -0.35 | -0.75 |
Gross Margin | 69.22% | 69.70% | 66.14% | 65.42% | 67.93% |
Operating Margin | -51.56% | -88.20% | -100.74% | -111.96% | -90.28% |
Profit Margin | -65.54% | -67.73% | -74.46% | -70.80% | -51.23% |
Free Cash Flow Margin | -29.01% | -75.68% | -186.41% | -94.18% | -202.80% |
EBITDA | -100.85 | -125.83 | -187.6 | -157.52 | -130.04 |
EBITDA Margin | -36.17% | -70.36% | -89.32% | -100.85% | -83.35% |
D&A For EBITDA | 42.91 | 31.9 | 24 | 17.35 | 10.82 |
EBIT | -143.77 | -157.73 | -211.6 | -174.87 | -140.86 |
EBIT Margin | -51.56% | -88.20% | -100.74% | -111.96% | -90.28% |
Revenue as Reported | - | 178.84 | 210.04 | 156.19 | 156.02 |
Advertising Expenses | - | 1.59 | 2.27 | 1.91 | 2.36 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.